Avantor Partners with BlueWhale Bio to Advance CAR-T Cell Therapy Manufacturing
Avantor, a global leader in life sciences and advanced technologies, has announced a strategic partnership with BlueWhale Bio, a commercial-stage company focused on transforming immune cell therapy manufacturing. The collaboration aims to streamline CAR-T production, reducing variability and time-to-patient while expanding access to life-saving therapies. The partnership brings together Avantor’s bioprocessing and custom reagent manufacturing expertise with BlueWhale Bio’s Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. Together, the organizations will accelerate the scale-up of CDNP manufacturing and produce GMP-grade CDNP materials to support next-generation cell therapy manufacturing. By combining technological innovation and biomanufacturing capabilities, Avantor and BlueWhale Bio aim to enhance production efficiency and capacity across the rapidly growing cell therapy sector.
Avantor Partners with BlueWhale Bio to Advance CAR-T Cell Therapy Manufacturing